Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

• Status: RECRUITING
• Trial end date: 2030-03-23

Summary

Our center plans to conduct a randomized, open-label, parallel-controlled, multi-center phase III study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Toripalimab for HR+/HER2- breast cancer. The aim is to further explore the treatment strategy of chemotherapy with immunotherapy for patients with HR+/HER2- breast cancer, provide more treatment options for breast cancer patients, and offer a potential theoretical basis for the precision treatment of breast cancer.The primary study objective is to evaluate the pathologic complete responsePCRand RCB0-1 ratio of neodjuvant treatment of HR+/HER2- breast cancer.

• Phase: PHASE3

Details

• Lead Sponsor: First Affiliated Hospital of Zhejiang University
• Treatments: Neoadjuvant Therapy; toripalimab